

Listing of the Claims:

The following is a complete listing of all the claims in the application, with an indication of the status of each:

1-9. (Canceled)

10. (Currently amended) A therapeutical composition containing dendritic cells (DC) and/or lymphocytes cocultivated with said DC, said DC have acquired the property to drive a T helper cell type I response, obtainable by a method according to claim 1 comprising the step of culturing the DC from any source in the presence of at least one interferon (IFN) gamma receptor agonist and of at least toll like receptor (TLR) 2 and TLR 6 agonist whereby said TLR 2 and TLR 6 agonist is a bisacyloxypropyl-S-cystein derivative.

11-24. (Canceled)

25. (New) The therapeutical composition according to claim 10 whereby said bisacyloxypropyl-S-cystein derivative is a lipopeptide derived from Mycoplasma fermentans or a corresponding synthetic lipopeptide capable of stimulating macrophages in vitro or in vivo.

26. (New) The therapeutical composition according to claim 10 whereby said bisacyloxypropyl-S-cystein derivative is a macrophage activating lipopeptide 2kDa (MALP-2) or a biologically active derivative thereof.

27. (New) The therapeutical composition according to claim 26 whereby said bisacyloxypropyl-S-cystein derivative is S-[2,3-bis(palmitoyloxy)-(2S)-propyl-L-cysteinyl-carboxy-polyethyleneglycol or S-[2,3-bis(palmitoyloxy)-(2R)-propyl-L-cysteinyl-carboxy-polyethyleneglycol .

28. (New) The therapeutical composition according to claim 10 wherein the IFN gamma receptor agonist is the appropriate species-specific IFN gamma or a variant thereof.

29. (New) The therepeutical composition according to claim 10 wherein the source of DC includes progenitor derived DC, in particular monocyte derived DC and stem cell derived DC, or in vivo existent DC, in particular blood derived DC, and wherein the DC are preferably derived from autologous monocytes of a person or animal to be treated with said composition.
30. (New) The therapeutical composition according to claim 10 comprising the step of washing the treated DC and resuspending said DC in water, saline or a physiological medium.
31. (New) The therapeutical composition according to claim 10 wherein the DC are loaded with antigens.
32. (New) The therapeutical composition according to claim 10 wherein the lymphocytes for cuculturing the DC are autologous or allergenic lymphocytes acquired from the peripheral blood of donors whereafter the DC and the lymphocytes and optionally, further ingredients are cocultivated for a time period of up to several days, preferably at least 24 hours and more preferred at least 3 days.
33. (New) The therapeutical composition according to claim 10 adapted as a vaccine for the treatment of malignancies, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation.
34. (New) A pharmaceutical composition comprising effective amounts of at least one interferon gamma receptor agonist and at least one TLR 2 and TLR 6 agonist and a pharmaceutically acceptable carrier and/or diluent whereby said at least one TLR 2 and TLR 6 agonist is a bisacyloxypropyl-S-cystein detivative.
35. (New) The pharmaceutical composition according to claim 34, wherein the bisacyloxypropyl-S-cystein derivative is a lipopeptide derived from Mycoplasma fermentans or a corresponding synthetic lipopeptide capable of stimulating

macrophages in vitro or in vivo.

36. (New) The pharmaceutical composition according to claim 34, whereby said bisacyloxypropyl-S-cystein derivative is a macrophage activating lipopeptide 2kDa (MALP-2) or a biologically active derivative thereof.

37. (New) The pharmaceutical composition according to claim 34 whereby said bisacyloxypropyl-S-cystein derivative is S-[2,3-bis(palmitoyloxy)-(2S)-propyl-L-cysteiny]-carboxy-polyethyleneglycol or S-[2,3-bis(palmitoyloxy)-(2R)-propyl-L-cysteiny]-carboxy-polyethyleneglycol .

38. (New) A method for treating a subject by immunotherapy comprising the step of administering to said subject in need thereof an effective amount of a therapeutical composition containing dendritic cells (DC) and/or lymphocytes cocultivated with said DC, said DC have acquired the property to drive a T helper cell type I response, obtainable by a method comprising the step of culturing the DC from any source in the presence of at least one interferon (IFN) gamma receptor agonist and of at least toll like receptor (TLR) 2 and TLR 6 agonist whereby said TLR 2 and TLR 6 agonist is a bisacyloxypropyl-S-cystein derivative.